Research output per year
Research output per year
Unit profile
Description
Ramin Massoumi is Research Group Leader for this research groupResearch
The main objective of our research is to understand landscape of post-translational modifications (PTM) in different types of human diseases including chronic inflammation and cancer. This is analyzed by functional characterization of enzymes involved in PTM and their related substrate in a tissue/cell specific manner. On this basis, the following key in vivo model systems are applied to meeting the above objectives: (1) Generating transgenic animals to define specific gene function. (2) Studying the function of the specific gene during progression of cancer which is followed after tumor induction in a specific organ in the animal. (3) Studying tissue samples from patients with cancer and correlating to the gene function and signaling pathway in animal. (4) Treatment of animals and the human tissue platforms with different drugs as suggested treatment methods in human cancer patients.UKÄ subject classification
- Cancer and Oncology
Free keywords
- Cancer therapy
- transgenic animals
- post-translational modification
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. Our work contributes towards the following SDG(s):
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Renée Daams
- Molecular Tumor Pathology - Doctoral student
- LUCC: Lund University Cancer Centre - Doctoral student
Person
-
Ramin Massoumi
- Division of Translational Cancer Research - Senior lecturer
- Molecular Tumor Pathology - Research team manager
- LUCC: Lund University Cancer Centre - Principal investigator
Person
-
Wondossen Sime
- Division of Translational Cancer Research - Research engineer
- Molecular Tumor Pathology - Research engineer
- LUCC: Lund University Cancer Centre - Research support
Person
-
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
Shah, K., Nasimian, A., Ahmed, M., Al Ashiri, L., Denison, L., Sime, W., Bendak, K., Kolosenko, I., Siino, V., Levander, F., Palm-Apergi, C., Massoumi, R., Lock, R. B. & Kazi, J. U., 2023 Dec, In: Blood Cancer Journal. 13, 1, 139.Research output: Contribution to journal › Article › peer-review
Open Access -
SPATA2 restricts OTULIN-dependent LUBAC activity independently of CYLD
Griewahn, L., Müller, M., Peintner, L., Wissler, M., Weiss, M., Brauns-Schubert, P., Massoumi, R., Borner, C., Groß, O., Yabal, M., Charvet, C. & Maurer, U., 2023 Jan, In: Cell Reports. 42, 1, 111961.Research output: Contribution to journal › Article › peer-review
Open Access -
Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis
Grigoryan, A., Zacharaki, D., Balhuizen, A., Côme, C. R., Garcia, A. G., Hidalgo Gil, D., Frank, A-K., Aaltonen, K., Mañas, A., Esfandyari, J., Kjellman, P., Englund, E., Rodriguez, C., Sime, W., Massoumi, R., Kalantari, N., Prithiviraj, S., Li, Y., Dupard, S. J., Isaksson, H., & 4 others, 2022 Oct 12, In: Science Translational Medicine. 14, 666, p. 1-15 eabm6391.Research output: Contribution to journal › Article › peer-review
Projects
Infrastructure
-
In vivo Imaging System Spectrum CT 3D
Ramin Massoumi (Manager)
Division of Translational Cancer ResearchInfrastructure